Hashimoto Shigeo, Kuroha Takashi, Yano Toshio, Sato Naoko, Furukawa Tatsuo
Department of Hematology, Nagaoka Red Cross Hospital, Japan.
Intern Med. 2016;55(20):3025-3028. doi: 10.2169/internalmedicine.55.6470. Epub 2016 Oct 15.
Five cases were treated by adding daily low-dose thalidomide (50 mg) to bortezomib and dexamethasone therapy for refractory multiple myeloma. This therapy was effective in four cases, with an improvement of bone pain and regression of M-protein. One case was treated with cyclophosphamide, thalidomide, and dexamethasone, adding bortezomib after starting the three-drug combination therapy. This patient has remained in a stable disease state since the beginning of this therapy. Regarding the other four cases, a partial response and a prolonged survival for approximately one year were noted. Peripheral neuropathy did not increase after thalidomide addition. Adding low-dose thalidomide may safely improve the responses for multiple myeloma refractory to bortezomib and dexamethasone.
对于5例难治性多发性骨髓瘤患者，在硼替佐米和地塞米松治疗的基础上，每日加用低剂量沙利度胺（50毫克）进行治疗。该疗法在4例患者中有效，患者骨痛得到改善，M蛋白水平下降。1例患者接受环磷酰胺、沙利度胺和地塞米松治疗，在三联疗法开始后加用硼替佐米。自该疗法开始以来，该患者病情一直保持稳定。关于其他4例患者，观察到部分缓解且生存期延长约一年。加用沙利度胺后周围神经病变未加重。加用低剂量沙利度胺可能安全地改善对硼替佐米和地塞米松难治的多发性骨髓瘤的反应。
